By Caroline Valetkevitch
New York (Reuters) – The New York Stock Exchange ended up on Tuesday against the fears aroused by the continuation of the conflict between Israel and Iran, and a possible involvement of the United States, and poor American macroeconomic indicators.
The Dow Jones index sold 0.70%, or 299.29 points, to 42,215.80 points. The larger Standard & Poor’s 500 lost 50.39 points, 0.84% ​​to 5,982.72 points. The Nasdaq Composite fell on its side of 180.12 points, or 0.91% to 19,521.091 points.
After calling for an “unconditional capitulation” of Iran, Donald Trump, who shorted his participation in a G7 summit on Monday in Canada, brought together his national security council in Washington. The American president said that the United States was not going to kill the Iranian supreme guide, Ali Khamenei, “at least for the moment”.
While Israel and Iran have been bombing for five days, Reuters reported, citing three American officials, that the United States would deploy air reinforcements in the Middle East.
“We are in a period when visibility is not good, the uncertainty is high, and the wall of concern is being built,” said Terry Sandven, actions strategist at Us Bank Wealth Management in Minneapolis.
Already concerned about Donald Trump’s regular reversals in terms of customs duties, investors also learned Tuesday that retail sales had dropped more strongly than expected last month in the United States while manufacturing production has barely increased.
Caution is also in place of the announcement of monetary policy of the Federal Reserve, even if the probability is strong of a status quo on interest rates.
All the S&P sectoral indices have finished in the red with the exception of energy, carried by the rise in oil prices due to tensions in the Middle East.
To individual values, companies in the solar energy sector suffered after the presentation on Monday evening by Republican senators from a gradual abolition of tax advantages for renewable energies. Enphase Energy fell 24% and Sunrun by 40%.
The title Eli Lilly sold 2% after the announcement of the acquisition of Verve Therapeutics (+81.5%) for $ 1.3 billion.
(With Kanchana Chakravarty and Sukriti Gupta in Bangalore, Bertrand Boucey)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
